REGENXBIO Inc.
RGNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $83,328 | $90,242 | $112,724 | $470,347 |
| % Growth | -7.7% | -19.9% | -76% | – |
| Cost of Goods Sold | $33,567 | $37,213 | $54,545 | $51,833 |
| Gross Profit | $49,761 | $53,029 | $58,179 | $418,514 |
| % Margin | 59.7% | 58.8% | 51.6% | 89% |
| R&D Expenses | $208,522 | $232,266 | $242,453 | $181,437 |
| G&A Expenses | $76,619 | $88,494 | $85,281 | $79,333 |
| SG&A Expenses | $76,619 | $88,494 | $85,281 | $79,333 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,034 | $397 | -$6,679 | -$2,236 |
| Operating Expenses | $283,107 | $321,157 | $321,055 | $258,534 |
| Operating Income | -$233,346 | -$268,128 | -$262,876 | $159,980 |
| % Margin | -280% | -297.1% | -233.2% | 34% |
| Other Income/Exp. Net | $6,244 | $4,482 | -$17,529 | -$18,733 |
| Pre-Tax Income | -$227,102 | -$263,646 | -$280,405 | $141,247 |
| Tax Expense | $0 | -$152 | -$84 | $13,407 |
| Net Income | -$227,102 | -$263,494 | -$280,321 | $127,840 |
| % Margin | -272.5% | -292% | -248.7% | 27.2% |
| EPS | -4.59 | -6.02 | -6.5 | 3.01 |
| % Growth | 23.8% | 7.4% | -315.9% | – |
| EPS Diluted | -4.59 | -6.02 | -6.5 | 2.91 |
| Weighted Avg Shares Out | 49,509 | 43,734 | 43,152 | 42,438 |
| Weighted Avg Shares Out Dil | 49,509 | 43,734 | 43,152 | 43,913 |
| Supplemental Information | – | – | – | – |
| Interest Income | $174 | $25 | $342 | $719 |
| Interest Expense | $12,659 | $6,862 | $23,254 | $26,277 |
| Depreciation & Amortization | $16,215 | $17,320 | $12,909 | $9,564 |
| EBITDA | -$198,228 | -$239,464 | -$244,242 | $169,544 |
| % Margin | -237.9% | -265.4% | -216.7% | 36% |